Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
06:00am, Wednesday, 28'th Jan 2026
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
01:10am, Tuesday, 27'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of
Cal-Maine Foods: Zero Debt, Massive Cash Position, And Ready For GLP-1 Tailwinds
05:32am, Saturday, 24'th Jan 2026
Cal-Maine Foods earns a reiterated buy rating, driven by rapid expansion into prepared foods and a strong, debt-free balance sheet. Prepared food sales surged 586.4% in Q2'FY26, backed by significant
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
12:45pm, Friday, 23'rd Jan 2026
Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill.
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
09:12am, Friday, 23'rd Jan 2026
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
10:05am, Wednesday, 21'st Jan 2026
Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing i
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
06:00pm, Thursday, 15'th Jan 2026
VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a contr
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
12:08pm, Wednesday, 14'th Jan 2026
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the comp
Is It Time to Dump Your Shares of Eli Lilly?
08:32am, Wednesday, 14'th Jan 2026
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug.
Global Partners: Upgrading To Strong Buy As Market Fear Creates Value
06:00am, Tuesday, 13'th Jan 2026
Global Partners LP is upgraded to Strong Buy, driven by a resilient business model, 16th consecutive distribution increase, and clear undervaluation. GLP maintains a robust ~7.08% yield with a managea
Global Partners LP Insider Purchases Nearly 4000 Shares To Close Out 2025
03:16am, Tuesday, 13'th Jan 2026
An insider of Global Partners LP acquired 3,917 shares of the company for a transaction value of $176,566.28 in December 2025. The transaction involved only direct ownership; no derivative, gifting, o
Novo Nordisk CEO: People have been waiting for a GLP-1 pill
07:41pm, Monday, 12'th Jan 2026
Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Novo Nordisk sees oral pills capturing over third of GLP-1 market by 2030
03:52pm, Monday, 12'th Jan 2026
Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the company originally anticipated, a Novo Nordisk executive said on Monday.
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
12:36pm, Monday, 12'th Jan 2026
Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives
